Pharm Eco Dno Andover

Bodycote Hot Isostatic Pressing provides various adding treatments for unconventional materials. The company serves the power generation, precision casting and tooling, automotive, architectural, construction, fire protection, aerospace, medical engineering, defense and chemical industries. Bodycote Hot Isostatic Pressing is a part of Bodycote, which is one of the leading providers of specialized testing and thermal processing services worldwide. The company additionally offers metallurgical coatings for anticorrosion, anticoking, metal cutting and forming, decorative, and wear, metal dusting and high-temperature resistance applications. Bodycote also provides duplex and plasma spray coatings. The company offers measurement services for calibrating services in electronic, dimension, torque, pressure, temperature, optical, flow and other physical parameters.

Paratek Pharmaceuticals, based in Boston, MA, is a biopharmaceutical company dedicated to addressing the critical global public health issue of antimicrobial resistance (AMR). With a focus on developing innovative treatment options for complex medical issues, Paratek is committed to combatting AMR through responsible antibiotic use, improved surveillance, and research into new antibiotics. Grounded in a mission to save lives, Paratek's FDA-approved tetracycline-class antibiotic, NUZYRA, targets adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. The company's disciplined team of experts is driven to provide new technologies that can defeat superbugs and contribute to a vibrant marketplace that recognizes the life-saving value of novel antibiotics.Generated from the website

Microbiotix is a privately held, product-focused biopharmaceutical company engaged in the research and development of novel small molecule, anti-infective drugs that address commercially significant medical markets. The company has four novel compound series in research and development. Microbiotix developed MBX 500, the first antibiotic that targets the deoxyribonucleic acid polymerase of gram-positive bacteria, including drug resistant strains. The company has an active research program to discover a broad-spectrum antibiotic that targets DNA replication of drug-resistant gram-positive and gram-negative bacteria. In addition to MBX 500, Microbiotix's most advanced antiviral compounds are for the treatment of respiratory syncytial virus (MBX 300) and cytomegalovirus (MBX400) which are in pre-clinical development. It also has an active biodefense program, focused on novel therapeutics for Bacillus Anthraocis and Burkholderia pseudomalli. Based in Worcester, Mass., Microbiotix is involved in the discovery of inhibitors of bacterial biofilm formation and antibiotic resistance.